C
BCRX icon

Covestor’s BioCryst Pharmaceuticals BCRX Stock Holding History

Covestor’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2K Buy
205
+115
+128% +$1.04K ﹤0.01% 1952
2026
Q1 		$1K Sell
90
-112
-55% -$870 ﹤0.01% 1973
2025
Q4 		$2K Sell
202
-1
-0.5% -$7 ﹤0.01% 1893
2025
Q3 		$2K Sell
203
-2
-1% -$17 ﹤0.01% 1917
2025
Q2 		$2K Sell
205
-51
-20% -$475 ﹤0.01% 1823
2025
Q1 		$2K Buy
256
+239
+1,406% +$1.93K ﹤0.01% 1816
2024
Q4 		$0 Buy
17
+1
+6% +$8 ﹤0.01% 2234
2024
Q3 		$0 Sell
16
-1
-6% -$8 ﹤0.01% 2216
2024
Q2 		$0 Hold
17
– – ﹤0.01% 2242
2024
Q1 		$0 Sell
17
-2
-11% -$11 ﹤0.01% 2235
2023
Q4 		$0 Buy
19
+3
+19% +$17 ﹤0.01% 2145
2023
Q3 		$0 Sell
16
-199
-93% -$1.43K ﹤0.01% 2112
2023
Q2 		$2K Sell
215
-43
-17% -$345 ﹤0.01% 1799
2023
Q1 		$2K Sell
258
-2
-0.8% -$19 ﹤0.01% 1736
2022
Q4 		$3K Buy
260
+115
+79% +$1.43K ﹤0.01% 1672
2022
Q3 		$2K Sell
145
-4
-3% -$51 ﹤0.01% 1677
2022
Q2 		$2K Buy
149
+1
+0.7% +$10 ﹤0.01% 1589
2022
Q1 		$2K Sell
148
-7
-5% -$112 ﹤0.01% 1655
2021
Q4 		$2K Buy
+155
New +$2.05K ﹤0.01% 1519

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Covestor's BCRX Position: Q2 2026 in Review

Covestor increased its BioCryst Pharmaceuticals (BCRX) stake by 128% in Q2 2026, buying an estimated $1.04K and bringing the position to 205 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #1952.

Covestor first reported a position in BCRX in Q4 2021 and has held it in 19 quarters since. The position peaked at $3K in Q4 2022. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Covestor held 205 shares of BioCryst Pharmaceuticals worth $2K as of Q2 2026.
  • Covestor bought 115 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $1.04K.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Covestor's portfolio in Q2 2026, its #1952 holding.
  • Covestor first reported a position in BioCryst Pharmaceuticals in Q4 2021 and has held it in 19 quarters since.
  • Covestor's BioCryst Pharmaceuticals position peaked at $3K in Q4 2022.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Covestor's 13F filing for Q2 2026, filed 7 Aug 2026.